Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis
Objective: The occurrence, development, and prognosis of serious adverse events (SAEs) associated with anticancer drugs in clinical trials have important guiding significance for real-world clinical applications. However, to date, there have been no studies investigating SAEs reporting in randomized...
Guardado en:
Autores principales: | Yanhong Yao, Zhentao Liu, Hua Zhang, Jian Li, Zhi Peng, Jinyu Yu, Baoshan Cao, Lin Shen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/60490e93b73749b4ba110cadce8e58ba |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effective Attributes in Colorectal Cancer Relapse Using Artificial Neural Network and Cox Proportional Hazards Regression
por: Saeedeh Pourahmad, et al.
Publicado: (2014) -
Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov
por: Kentaro Sakamaki, et al.
Publicado: (2021) -
Applications of proportional calculus and a non-Newtonian logistic growth model
por: Pinto,Manuel, et al.
Publicado: (2020) -
Fecal Metabolomic Signatures in Colorectal Adenoma Patients Are Associated with Gut Microbiota and Early Events of Colorectal Cancer Pathogenesis
por: Minsuk Kim, et al.
Publicado: (2020) -
Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer
por: Ilfad Blazevic, et al.
Publicado: (2020)